Tumor suppressor protein Pdcd4 interacts with Daxx and modulates the stability of Daxx and the Hipk2-dependent phosphorylation of p53 at serine 46

被引:27
|
作者
Kumar, N. [1 ,2 ]
Wethkamp, N. [1 ]
Waters, L. C. [3 ]
Carr, M. D. [3 ]
Klempnauer, K-H [1 ]
机构
[1] Univ Munster, Inst Biochem, D-48149 Munster, Germany
[2] Univ Munster, Grad Sch Chem GSC MS, D-48149 Munster, Germany
[3] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England
来源
ONCOGENESIS | 2013年 / 2卷
基金
英国惠康基金;
关键词
Pdcd4; Daxx; protein-protein interaction; p53; TRANSCRIPTIONAL ACTIVITY; BINDING-PROTEIN; EUKARYOTIC TRANSLATION; INHIBITS TRANSLATION; HISTONE CHAPERONE; SUMO MODIFICATION; STRUCTURAL BASIS; GENE-EXPRESSION; TRANSFORMATION; APOPTOSIS;
D O I
10.1038/oncsis.2012.37
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The tumor suppressor protein Pdcd4 is a nuclear/cytoplasmic shuttling protein that has been implicated in the development of several types of human cancer. In the nucleus, Pdcd4 affects the transcription of specific genes by modulating the activity of several transcription factors. We have identified the Daxx protein as a novel interaction partner of Pdcd4. Daxx is a scaffold protein with roles in diverse processes, including transcriptional regulation, DNA-damage signaling, apoptosis and chromatin remodeling. We show that the interaction of both proteins is mediated by the N-terminal domain of Pdcd4 and the central part of Daxx, and that binding to Pdcd4 stimulates the degradation of Daxx, presumably by disrupting the interaction of Daxx with the de-ubiquitinylating enzyme Hausp. Daxx has previously been shown to serve as a scaffold for protein kinase Hipk2 and tumor suppressor protein p53 and to stimulate the phosphorylation of p53 at serine 46 (Ser-46) in response to genotoxic stress. We show that Pdcd4 also disrupts the Daxx-Hipk2 interaction and inhibits the phosphorylation of p53. We also show that ultraviolet irradiation decreases the expression of Pdcd4. Taken together, our results support a model in which Pdcd4 serves to suppress the phosphorylation of p53 in the absence of DNA damage, while the suppressive effect of Pdcd4 is abrogated after DNA damage owing to the decrease of Pdcd4. Overall, our data demonstrate that Pdcd4 is a novel modulator of Daxx function and provide evidence for a role of Pdcd4 in restraining p53 activity in unstressed cells.
引用
收藏
页码:e37 / e37
页数:9
相关论文
共 25 条
  • [21] The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53
    Pomerantz, J
    Schreiber-Agus, N
    Liegeois, NJ
    Silverman, A
    Alland, L
    Chin, L
    Potes, J
    Chen, K
    Orlow, I
    Lee, HW
    Cordon-Cardo, C
    DePinho, RA
    CELL, 1998, 92 (06) : 713 - 723
  • [22] Loss of fragile X protein FMRP impairs homeostatic synaptic downscaling through tumor suppressor p53 and ubiquitin E3 ligase Nedd4-2
    Lee, Kwan Young
    Jewett, Kathryn A.
    Chung, Hee Jung
    Tsai, Nien-Pei
    HUMAN MOLECULAR GENETICS, 2018, 27 (16) : 2805 - 2816
  • [23] Recognition of DNA modified by trans-[PtCl2NH3(4-hydroxymethylpyridine)] by tumor suppressor protein p53 and character of DNA adducts of this cytotoxic complex
    Stehlíková, K
    Kaspárková, J
    Nováková, O
    Martínez, A
    Moreno, V
    Brabec, V
    FEBS JOURNAL, 2006, 273 (02) : 301 - 314
  • [24] Tumor Suppressor Protein p53 Promotes 2-Methoxyestradiol-Induced Activation of Bak and Bax, Leading to Mitochondria-Dependent Apoptosis in Human Colon Cancer HCT116 Cells
    Lee, Ji Young
    Jee, Su Bean
    Park, Won Young
    Choi, Yu Jin
    Kim, Bokyung
    Kim, Yoon Hee
    Jun, Do Youn
    Kim, Young Ho
    JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2014, 24 (12) : 1654 - 1663
  • [25] Discordant hepatic expression of the cell division control enzyme p34(cdc2) kinase, proliferating cell nuclear antigen, p53 tumor suppressor protein, and p21(Waf1) cyclin-dependent kinase inhibitory protein after WY14,643 ([4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid) dosing to rats
    Ma, XF
    Stoffregen, DA
    Wheelock, GD
    Rininger, JA
    Babish, JG
    MOLECULAR PHARMACOLOGY, 1997, 51 (01) : 69 - 78